A look back at 2022: anniversary, acquisition and accreditation
As the year draws to a close, I would like to take this opportunity to reflect on our achievements this year.
2022 began with considerable excitement as we received ISO/IEC 17025:2017 accreditation, an official statement that our genetic QC services are operated within a robustly reliable compliant framework.
This year also marked an important milestone for Cergentis as we celebrated our ten-year anniversary. As a co-founder, it has been an inspiring and rewarding journey to witness the accelerated growth of our company from an early-stage biotech start-up to a fully-fledged global scale-up business. Along the way, we have had the pleasure to forge world-class partnerships. Our latest joint white paper with Horizon Discovery is another testament of our global recognition as a leading and trusted genetic testing service provider.
With Joris Schuurmans departing for new endeavors, the entire team is overcome by a mixed sense of loss and gratitude for his transformative contributions. Joris had the challenging task of navigating the company through the difficult COVID-19 pandemic. Nevertheless, his wealth of experience combined with his visionary leadership led us to join Solvias in July, one of the world's leading independent pharmaceutical testing and manufacturing companies. This is a major achievement for Cergentis and a true recognition of our ability to deliver high-quality services. I am positive that this acquisition will present more opportunities for growth as we both combine our complementary expertise. Above all, this reinforces a shared and deep commitment to providing our customers across the globe with the highest quality solutions and support to safely get their products into the hands of patients as quickly as possible.
Furthermore, I wish to express my gratitude to our entire staff for their relentless efforts and resolute commitment. Unquestionably, our continued growth and success are built on their dedication and invaluable contributions.
Finally, Cergentis is equally blessed by its customers’ unwavering commitment and trust, allowing us to contribute to their important and groundbreaking R&D and whose feedback remains instrumental in helping us improve the quality of our data and offerings. We are beyond proud that many of you have become true Cergentis and TLA ambassadors over the last decade, and that we are still able to keep welcoming new customers every year. As the new General Manager, I therefore vow to maintain a customer-centric approach, and ensure that we continue addressing and supporting the most pressing genetic characterization and QC issues that the biomedical community is confronted with.
In sum, we can take pride in our many great and hard-earned accomplishments over the last decade and look to the future with optimism. With festivities around the corner, I wish our customers, employees and partners, healthy and happy holidays.
Erik Splinter
